The EMA has started a review of Leo Pharma’s interleukin-13 inhibitor tralokinumab as an antibody therapy for atopic dermatitis, a category that is currently dominated by Sanof
Oxford Biomedica’s long-running alliance with Sanofi over a pair of gene therapies for ophthalmic diseases has come to an end, after an internal review by the French drugmaker.
President Donald Trump’s Operation Warp Speed, which aims to make a coronavirus vaccine widely available by year-end, has come up with a shortlist of candidates, with some nota
Sanofi’s new multiple myeloma drug Sarclisa (isatuximab) has been approved in the EU for relapsed/refractory disease, taking on Johnson & Johnson’s well-established blockbuster Darzalex
Sanofi's new CEO Paul Hudson has completed his revamp of the company’s executive committee, including the appointment of a dedicated chief digital officer.
Sanofi and Regeneron’s once close relationship has been become a little more distant over the last couple of years, and the process continued this week after Sanofi said it wil